The crosstalk of PTGS2 and EGF signaling pathways in colorectal cancer

Cancers

Volumn 3, Issue 4, 2011, Pages 3894-3908

  Wang, Dingzhi ^a   Xia, Dianren ^a   DuBois, Raymond N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Colorectal cancer; COX 2; EGFR; PTGS2

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; CETUXIMAB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MICRORNA; NONSTEROID ANTIINFLAMMATORY AGENT; PANITUMUMAB; PROSTAGLANDIN E2;

CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER PREVENTION; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; CYCLOOXYGENASE 2 GENE; DISEASE ASSOCIATION; DRUG TARGETING; GENE; GENE DELETION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; INTRACELLULAR SIGNALING; METASTASIS; MOLECULAR INTERACTION; MONOTHERAPY; NONHUMAN; RECEPTOR BINDING; REVIEW; TRANSACTIVATION; TRANSCRIPTION REGULATION; TUMOR GROWTH;

EID: 84055190414     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3043894     Document Type: Review

References (94)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58, 71-96.
2. Woutersen, R.A.; Appel, M.J.; van Garderen-Hoetmer, A.; Wijnands, M.V. Dietary fat and carcinogenesis. Mutat. Res. 1999, 443, 111-127.
3. Powell, S.M.; Zilz, N.; Beazer-Barclay, Y.; Bryan, T.M.; Hamilton, S.R.; Thibodeau, S.N.; Vogelstein, B.; Kinzler, K.W. APC mutations occur early during colorectal tumorigenesis. Nature 1992, 359, 235-237.
4. Jen, J.; Powell, S.M.; Papadopoulos, N.; Smith, K.J.; Hamilton, S.R.; Vogelstein, B.; Kinzler, K.W. Molecular determinants of dysplasia in colorectal lesions. Cancer Res. 1994, 54, 5523-5526.
5. Smith, A.J.; Stern, H.S.; Penner, M.; Hay, K.; Mitri, A.; Bapat, B.V.; Gallinger, S. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res. 1994, 54, 5527-5530.
6. Eberhart, C.E.; Coffey, R.J.; Radhika, A.; Giardiello, F.M.; Ferrenbach, S.; DuBois, R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107, 1183-1188.
7. de Groot, D.J.; de Vries, E.G.; Groen, H.J.; de Jong, S. Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: From lab to clinic. Crit. Rev. Oncol. Hematol. 2007, 61, 52-69.
8. Wang, D.; Dubois, R.N. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2009, 29, 781-788.
9. Saltz, L.B.; Meropol, N.J.; Loehrer, P.J., Sr.; Needle, M.N.; Kopit, J.; Mayer, R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22, 1201-1208.
10. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351, 337-345.
11. Meyerhardt, J.A.; Mayer, R.J. Systemic therapy for colorectal cancer. N. Engl. J. Med. 2005, 352, 476-487.
12. Van Cutsem, E.; Peeters, M.; Siena, S.; Humblet, Y.; Hendlisz, A.; Neyns, B.; Canon, J.L.; Van Laethem, J.L.; Maurel, J.; Richardson, G.; et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 2007, 25, 1658-1664.
13. Smalley, W.E.; DuBois, R.N. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Pharmacol. 1997, 39, 1-20.
14. Chan, A.T.; Ogino, S.; Fuchs, C.S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 2007, 356, 2131-2142.
15. Chan, A.T.; Ogino, S.; Fuchs, C.S. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009, 302, 649-658.
16. Cuzick, J.; Otto, F.; Baron, J.A.; Brown, P.H.; Burn, J.; Greenwald, P.; Jankowski, J.; La Vecchia, C.; Meyskens, F.; Senn, H.J.; Thun, M. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: An international consensus statement. Lancet Oncol. 2009, 10, 501-507.
17. Harris, R.E. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009, 17, 55-67.
18. Graham, D.J.; Campen, D.; Hui, R.; Spence, M.; Cheetham, C.; Levy, G.; Shoor, S.; Ray, W.A. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 2005, 365, 475-481.
19. Fitzgerald, G.A. Coxibs and cardiovascular disease. N. Engl. J. Med. 2004, 351, 1709-1711.
20. Wang, D.; Mann, J.R.; DuBois, R.N. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 2005, 128, 1445-1461.
21. Dubois, R.N.; Abramson, S.B.; Crofford, L.; Gupta, R.A.; Simon, L.S.; Van De Putte, L.B.; Lipsky, P.E. Cyclooxygenase in biology and disease. FASEB J. 1998, 12, 1063-1073.
22. Young, L.E.; Sanduja, S.; Bemis-Standoli, K.; Pena, E.A.; Price, R.L.; Dixon, D.A. The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology 2009, 136, 1669-1679.
23. Strillacci, A.; Griffoni, C.; Sansone, P.; Paterini, P.; Piazzi, G.; Lazzarini, G.; Spisni, E.; Pantaleo, M.A.; Biasco, G.; Tomasi, V. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp. Cell Res. 2009, 315, 1439-1447.
24. Daikoku, T.; Hirota, Y.; Tranguch, S.; Joshi, A.R.; DeMayo, F.J.; Lydon, J.P.; Ellenson, L.H.; Dey, S.K. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res. 2008, 68, 5619-5627.
25. Kaidi, A.; Qualtrough, D.; Williams, A.C.; Paraskeva, C. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res. 2006, 66, 6683-6691.
26. Gupta, R.A.; Dubois, R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 2001, 1, 11-21.
27. Marnett, L.J.; DuBois, R.N. COX-2: A target for colon cancer prevention. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 55-80.
28. Ogino, S.; Kirkner, G.J.; Nosho, K.; Irahara, N.; Kure, S.; Shima, K.; Hazra, A.; Chan, A.T.; Dehari, R.; Giovannucci, E.L.; Fuchs, C.S. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin. Cancer Res. 2008, 14, 8221-8227.
29. Chulada, P.C.; Thompson, M.B.; Mahler, J.F.; Doyle, C.M.; Gaul, B.W.; Lee, C.; Tiano, H.F.; Morham, S.G.; Smithies, O.; Langenbach, R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 2000, 60, 4705-4708.
30. Oshima, M.; Dinchuk, J.E.; Kargman, S.L.; Oshima, H.; Hancock, B.; Kwong, E.; Trzaskos, J.M.; Evans, J.F.; Taketo, M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87, 803-809.
31. Al-Salihi, M.A.; Terrece Pearman, A.; Doan, T.; Reichert, E.C.; Rosenberg, D.W.; Prescott, S.M.; Stafforini, D.M.; Topham, M.K. Transgenic expression of cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression. Cancer Lett. 2009, 273, 225-232.
32. Rigas, B.; Goldman, I.S.; Levine, L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 1993, 122, 518-523.
33. Wang, D.; Dubois, R.N. Cyclooxygenase-2: A potential target in breast cancer. Semin. Oncol. 2004, 31, 64-73.
34. McLemore, T.L.; Hubbard, W.C.; Litterst, C.L.; Liu, M.C.; Miller, S.; McMahon, N.A.; Eggleston, J.C.; Boyd, M.R. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res. 1988, 48, 3140-3147.
35. Hambek, M.; Baghi, M.; Wagenblast, J.; Schmitt, J.; Baumann, H.; Knecht, R. Inverse correlation between serum PGE2 and T classification in head and neck cancer. Head Neck 2007, 29, 244-248.
36. Cai, Q.; Gao, Y.T.; Chow, W.H.; Shu, X.O.; Yang, G.; Ji, B.T.; Wen, W.; Rothman, N.; Li, H.L.; Morrow, J.D.; Zheng, W. Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J. Clin. Oncol. 2006, 24, 5010-5016.
37. Johnson, J.C.; Schmidt, C.R.; Shrubsole, M.J.; Billheimer, D.D.; Joshi, P.R.; Morrow, J.D.; Heslin, M.J.; Washington, M.K.; Ness, R.M.; Zheng, W.; et al. Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin. Gastroenterol. Hepatol. 2006, 4, 1358-1365.
38. Kekatpure, V.D.; Boyle, J.O.; Zhou, X.K.; Duffield-Lillico, A.J.; Gross, N.D.; Lee, N.Y.; Subbaramaiah, K.; Morrow, J.D.; Milne, G.; Lippman, S.M.; Dannenberg, A.J. Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients. Cancer Prev. Res. (Phila.) 2009, 2, 957-965.
39. Dong, L.M.; Shu, X.O.; Gao, Y.T.; Milne, G.; Ji, B.T.; Yang, G.; Li, H.L.; Rothman, N.; Zheng, W.; Chow, W.H.; Abnet, C.C. Urinary prostaglandin E2 metabolite and gastric cancer risk in the Shanghai women's health study. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 3075-3078.
40. Backlund, M.G.; Mann, J.R.; Holla, V.R.; Buchanan, F.G.; Tai, H.H.; Musiek, E.S.; Milne, G.L.; Katkuri, S.; DuBois, R.N. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J. Biol. Chem. 2005, 280, 3217-3223.
41. Wolf, I.; O'Kelly, J.; Rubinek, T.; Tong, M.; Nguyen, A.; Lin, B.T.; Tai, H.H.; Karlan, B.Y.; Koeffler, H.P. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res. 2006, 66, 7818-7823.
42. Hughes, D.; Otani, T.; Yang, P.; Newman, R.A.; Yantiss, R.K.; Altorki, N.K.; Port, J.L.; Yan, M.; Markowitz, S.D.; Mazumdar, M.; et al. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev. Res. (Phila.) 2008, 1, 241-249.
43. Thiel, A.; Ganesan, A.; Mrena, J.; Junnila, S.; Nykanen, A.; Hemmes, A.; Tai, H.H.; Monni, O.; Kokkola, A.; Haglund, C.; Petrova, T.V.; Ristimaki, A. 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin. Cancer Res. 2009, 15, 4572-4580.
44. Hansen-Petrik, M.B.; McEntee, M.F.; Jull, B.; Shi, H.; Zemel, M.B.; Whelan, J. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res. 2002, 62, 403-408.
45. Yan, M.; Myung, S.J.; Fink, S.P.; Lawrence, E.; Lutterbaugh, J.; Yang, P.; Zhou, X.; Liu, D.; Rerko, R.M.; Willis, J.; et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc. Natl. Acad. Sci. USA 2009, 106, 9409-9413.
46. Kawamori, T.; Uchiya, N.; Sugimura, T.; Wakabayashi, K. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 2003, 24, 985-990.
47. Wang, D.; Wang, H.; Shi, Q.; Katkuri, S.; Walhi, W.; Desvergne, B.; Das, S.K.; Dey, S.K.; DuBois, R.N. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 2004, 6, 285-295.
48. Myung, S.J.; Rerko, R.M.; Yan, M.; Platzer, P.; Guda, K.; Dotson, A.; Lawrence, E.; Dannenberg, A.J.; Lovgren, A.K.; Luo, G.; et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc. Natl. Acad. Sci. USA 2006, 103, 12098-12102.
49. Nakanishi, M.; Montrose, D.C.; Clark, P.; Nambiar, P.R.; Belinsky, G.S.; Claffey, K.P.; Xu, D.; Rosenberg, D.W. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res. 2008, 68, 3251-3259.
50. Watanabe, K.; Kawamori, T.; Nakatsugi, S.; Ohta, T.; Ohuchida, S.; Yamamoto, H.; Maruyama, T.; Kondo, K.; Ushikubi, F.; Narumiya, S.; et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res. 1999, 59, 5093-5096.
51. Mutoh, M.; Watanabe, K.; Kitamura, T.; Shoji, Y.; Takahashi, M.; Kawamori, T.; Tani, K.; Kobayashi, M.; Maruyama, T.; Kobayashi, K.; et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 2002, 62, 28-32.
52. Sonoshita, M.; Takaku, K.; Sasaki, N.; Sugimoto, Y.; Ushikubi, F.; Narumiya, S.; Oshima, M.; Taketo, M.M. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat. Med. 2001, 7, 1048-1051.
53. Hynes, N.E.; Lane, H.A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5, 341-354.
54. Sheng, H.; Shao, J.; Townsend, C.M., Jr.; Evers, B.M. Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells. Gut 2003, 52, 1472-1478.
55. Phillips, W.A.; St Clair, F.; Munday, A.D.; Thomas, R.J.; Mitchell, C.A. Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors. Cancer 1998, 83, 41-47.
56. Half, E.; Broaddus, R.; Danenberg, K.D.; Danenberg, P.V.; Ayers, G.D.; Sinicrope, F.A. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int. J. Cancer 2004, 108, 540-548.
57. Yasui, W.; Sumiyoshi, H.; Hata, J.; Kameda, T.; Ochiai, A.; Ito, H.; Tahara, E. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res. 1988, 48, 137-141.
58. Ciardiello, F.; Kim, N.; Saeki, T.; Dono, R.; Persico, M.G.; Plowman, G.D.; Garrigues, J.; Radke, S.; Todaro, G.J.; Salomon, D.S. Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc. Natl. Acad. Sci. USA 1991, 88, 7792-7796.
59. Tampellini, M.; Longo, M.; Cappia, S.; Bacillo, E.; Alabiso, I.; Volante, M.; Dogliotti, L.; Papotti, M. Co-expression of EGF receptor, TGFalpha and S6 kinase is significantly associated with colorectal carcinomas with distant metastases at diagnosis. Virchows Arch. 2007, 450, 321-328.
60. Cohen, G.; Mustafi, R.; Chumsangsri, A.; Little, N.; Nathanson, J.; Cerda, S.; Jagadeeswaran, S.; Dougherty, U.; Joseph, L.; Hart, J.; et al. Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci. Cancer Res. 2006, 66, 5656-5664.
61. Messa, C.; Russo, F.; Caruso, M.G.; Di Leo, A. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol. 1998, 37, 285-289.
62. Hayashi, Y.; Widjono, Y.W.; Ohta, K.; Hanioka, K.; Obayashi, C.; Itoh, K.; Imai, Y.; Itoh, H. Expression of EGF, EGF-receptor, p53, v-erb B and ras p21 in colorectal neoplasms by immunostaining paraffin-embedded tissues. Pathol. Int. 1994, 44, 124-130.
63. Radinsky, R. Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment. Cancer Metastasis Rev. 1995, 14, 323-338.
64. Lockhart, A.C.; Berlin, J.D. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin. Oncol. 2005, 32, 52-60.
65. Moran, A.E.; Hunt, D.H.; Javid, S.H.; Redston, M.; Carothers, A.M.; Bertagnolli, M.M. Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J. Biol. Chem. 2004, 279, 43261-43272.
66. Roberts, R.B.; Min, L.; Washington, M.K.; Olsen, S.J.; Settle, S.H.; Coffey, R.J.; Threadgill, D.W. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc. Natl. Acad. Sci. USA 2002, 99, 1521-1526.
67. Fichera, A.; Little, N.; Jagadeeswaran, S.; Dougherty, U.; Sehdev, A.; Mustafi, R.; Cerda, S.; Yuan, W.; Khare, S.; Tretiakova, M.; et al. Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Cancer Res. 2007, 67, 827-835.
68. Dougherty, U.; Sehdev, A.; Cerda, S.; Mustafi, R.; Little, N.; Yuan, W.; Jagadeeswaran, S.; Chumsangsri, A.; Delgado, J.; Tretiakova, M.; et al. Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Clin. Cancer Res. 2008, 14, 2253-2262.
69. Brandt, R.; Eisenbrandt, R.; Leenders, F.; Zschiesche, W.; Binas, B.; Juergensen, C.; Theuring, F. Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation. Oncogene 2000, 19, 2129-2137.
70. Jhawer, M.; Goel, S.; Wilson, A.J.; Montagna, C.; Ling, Y.H.; Byun, D.S.; Nasser, S.; Arango, D.; Shin, J.; Klampfer, L.; et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 2008, 68, 1953-1961.
71. Normanno, N.; Tejpar, S.; Morgillo, F.; De Luca, A.; Van Cutsem, E.; Ciardiello, F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat. Rev. Clin. Oncol. 2009, 6, 519-527.
72. Buchanan, F.G.; Wang, D.; Bargiacchi, F.; DuBois, R.N. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J. Biol. Chem. 2003, 278, 35451-35457.
73. Buchanan, F.G.; Gorden, D.L.; Matta, P.; Shi, Q.; Matrisian, L.M.; DuBois, R.N. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc. Natl. Acad. Sci. USA 2006, 103, 1492-1497.
74. Kelloff, G.; Fay, J.; Steele, V.; Lubet, R.; Boone, C.; Crowell, J.; Sigman, C. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomarkers Prev. 1996, 5, 657-666.
75. Yoshimoto, T.; Takahashi, Y.; Kinoshita, T.; Sakashita, T.; Inoue, H.; Tanabe, T. Growth stimulation and epidermal growth factor receptor induction in cyclooxygenase-overexpressing human colon carcinoma cells. Adv. Exp. Med. Biol. 2002, 507, 403-407.
76. Han, C.; Michalopoulos, G.K.; Wu, T. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J. Cell. Physiol. 2006, 207, 261-270.
77. Pai, R.; Soreghan, B.; Szabo, I.L.; Pavelka, M.; Baatar, D.; Tarnawski, A.S. Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 2002, 8, 289-293.
78. Al-Salihi, M.A.; Ulmer, S.C.; Doan, T.; Nelson, C.D.; Crotty, T.; Prescott, S.M.; Stafforini, D.M.; Topham, M.K. Cyclooxygenase-2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and tumor necrosis factor-alpha converting enzyme. Cell. Signal. 2007, 19, 1956-1963.
79. Shao, J.; Lee, S.B.; Guo, H.; Evers, B.M.; Sheng, H. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res. 2003, 63, 5218-5223.
80. Castellone, M.D.; Teramoto, H.; Williams, B.O.; Druey, K.M.; Gutkind, J.S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005, 310, 1504-1510.
81. Coffey, R.J.; Hawkey, C.J.; Damstrup, L.; Graves-Deal, R.; Daniel, V.C.; Dempsey, P.J.; Chinery, R.; Kirkland, S.C.; DuBois, R.N.; Jetton, T.L.; Morrow, J.D. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc. Natl. Acad. Sci. USA 1997, 94, 657-662.
82. Pham, H.; Chong, B.; Vincenti, R.; Slice, L.W. Ang II and EGF synergistically induce COX-2 expression via CREB in intestinal epithelial cells. J. Cell. Physiol. 2008, 214, 96-109.
83. Hobbs, S.S.; Goettel, J.A.; Liang, D.; Yan, F.; Edelblum, K.L.; Frey, M.R.; Mullane, M.T.; Polk, D.B. TNF transactivation of EGFR stimulates cytoprotective COX-2 expression in gastrointestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 301, G220-G229.
84. Cao, S.; Yan, Y.; Zhang, X.; Zhang, K.; Liu, C.; Zhao, G.; Han, J.; Dong, Q.; Shen, B.; Wu, A.; Cui, J. EGF stimulates cyclooxygenase-2 expression through the STAT5 signaling pathway in human lung adenocarcinoma A549 cells. Int. J. Oncol. 2011, 39, 383-391.
85. Wang, D.; Buchanan, F.G.; Wang, H.; Dey, S.K.; DuBois, R.N. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res. 2005, 65, 1822-1829.
86. Krysan, K.; Reckamp, K.L.; Dalwadi, H.; Sharma, S.; Rozengurt, E.; Dohadwala, M.; Dubinett, S.M. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptorindependent manner. Cancer Res. 2005, 65, 6275-6281.
87. Sheng, H.; Shao, J.; Morrow, J.; Beauchamp, R.D.; DuBois, R.N. Modulation of apoptosis by prostaglandin treatment in human colon cancer cells. Cancer Res. 1998, 58, 362-366.
88. Poligone, B.; Baldwin, A.S. Positive and negative regulation of NF-kappaB by COX-2: Roles of different prostaglandins. J. Biol. Chem. 2001, 276, 38658-38664.
89. Ito, H.; Duxbury, M.; Benoit, E.; Clancy, T.E.; Zinner, M.J.; Ashley, S.W.; Whang, E.E. Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res. 2004, 64, 7439-7446.
90. Pan, M.R.; Hou, M.F.; Chang, H.C.; Hung, W.C. Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. J. Biol. Chem. 2008, 283, 11155-11163.
91. Mann, M.; Sheng, H.; Shao, J.; Williams, C.S.; Pisacane, P.I.; Sliwkowski, M.X.; DuBois, R.N. Targeting cyclooxygenase 2 and her-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001, 120, 1713-1719.
92. Tortora, G.; Caputo, R.; Damiano, V.; Melisi, D.; Bianco, R.; Fontanini, G.; Veneziani, B.M.; De Placido, S.; Bianco, A.R.; Ciardiello, F. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin. Cancer Res. 2003, 9, 1566-1572.
93. Torrance, C.J.; Jackson, P.E.; Montgomery, E.; Kinzler, K.W.; Vogelstein, B.; Wissner, A.; Nunes, M.; Frost, P.; Discafani, C.M. Combinatorial chemoprevention of intestinal neoplasia. Nature Med. 2000, 6, 1024-1028.
94. Buchanan, F.G.; Holla, V.; Katkuri, S.; Matta, P.; DuBois, R.N. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res. 2007, 67, 9380-9388